<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty-one patients with <z:mp ids='MP_0002038'>carcinoma</z:mp> arising in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> were treated surgically from 1971 to 1990 </plain></SENT>
<SENT sid="1" pm="."><plain>This represented 10.2% of <z:hpo ids='HP_0000001'>all</z:hpo> treated cases with <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> during the same period </plain></SENT>
<SENT sid="2" pm="."><plain>The mean age was 63 years </plain></SENT>
<SENT sid="3" pm="."><plain>The most common symptom was <z:hpo ids='HP_0002015'>dysphagia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>According to PTNM staging, 18 were stage II, 24 stage III and 4 stage IV </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were treated by surgery </plain></SENT>
<SENT sid="6" pm="."><plain>The 30-day hospital mortality was 3.9% </plain></SENT>
<SENT sid="7" pm="."><plain>The one, two and five-year survival rates were 45.9%, 25.0% and 13.6%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The 5-year survival rate was significant greater for stage II (25.0%) than for stage III + IV patients (4.5%), and for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> length &lt; 6 cm (21.0%) than for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> length &gt; 6 cm (0) </plain></SENT>
<SENT sid="9" pm="."><plain>The results indicate that the survival rate following resection is closely related to the clinical stage and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size </plain></SENT>
</text></document>